U.S. STOCKS ON THE MOVE-Ford, Adobe, Accenture, Moderna, Avaya
Brief: BeyondSpring Gives Positive Data With Plinabulin For Prevention Of Docetaxel-Induced Neutropenia
Brief: Beyondspring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Beyondspring Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Beyondspring Presents New Clinical Evidence Of Plinabulin Protection Of Granulocyte-Monocyte Progenitor Stem Cells For The Prevention Of Chemotherapy-Induced Neutropenia At The ESMO Congress 2022
Beyondspring Inc expected to post a loss of 23 cents a share - Earnings Preview
Beyondspring Inc expected to post a loss of 23 cents a share - Earnings Preview
Beyondspring Inc reports results for the quarter ended in December - Earnings Summary
Beyondspring Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Beyondspring Announces Organizational Streamlining
Beyondspring Inc reports results for the quarter ended in September - Earnings Summary
Brief: Beyondspring Reports Qtrly Loss Per Share $0.47
Brief: Beyondspring Pharmaceuticals Announces Analysis Of New Data On The Plinabulin/Pegfilgrastim Combination In Breast Cancer
Jefferies, Wainwright downgrade BeyondSpring after FDA decision
U.S. RESEARCH ROUNDUP-Beyondspring, Okta, Vocera Communications
U.S. STOCKS ON THE MOVE-Ambarella, BeyondSpring, OceanPal, Allbirds
U.S. STOCKS ON THE MOVE-Box, BeyondSpring, Build-A-Bear Workshop, OceanPal
BeyondSpring dives after FDA declines to approve blood disorder drug
U.S. FDA declines to approve BeyondSpring's neutropenia drug, shares plunge (updated)